Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients

Affiliations

¹ CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France.
² Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.
³ Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France.
⁴ Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France.
⁵ Service d'Hématologie, Institut Bergonié, Bordeaux, France.
⁶ Neurooncology Department, Assistance Publique - Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
⁷ Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France.
⁸ AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France.
⁹ Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France.
¹⁰ Service d'Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France.
¹¹ Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France.
¹² Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France.
¹³ Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France. carole.soussain@curie.fr.
¹⁴ Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France. carole.soussain@curie.fr.

Published Erratum

Marion Alcantara et al. J Hematol Oncol. 2024.

. 2024 Oct 19;17(1):98.

doi: 10.1186/s13045-024-01620-y.

¹ CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France.
² Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France.
³ Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France.
⁴ Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France.
⁵ Service d'Hématologie, Institut Bergonié, Bordeaux, France.
⁶ Neurooncology Department, Assistance Publique - Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
⁷ Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France.
⁸ AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France.
⁹ Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France.
¹⁰ Service d'Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France.
¹¹ Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France.
¹² Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France.
¹³ Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France. carole.soussain@curie.fr.
¹⁴ Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France. carole.soussain@curie.fr.

No abstract available

Erratum for

Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
Alcantara M, Chevrier M, Jardin F, Schmitt A, Houillier C, Oberic L, Chinot O, Morschhauser F, Peyrade F, Houot R, Hoang-Xuan K, Ghesquieres H, Soussain C. Alcantara M, et al. J Hematol Oncol. 2024 Sep 19;17(1):86. doi: 10.1186/s13045-024-01606-w. J Hematol Oncol. 2024. PMID: 39300447 Free PMC article. Clinical Trial.